Li, Alexander H.
Hanchard, Neil A.
Azamian, Mahshid
D’Alessandro, Lisa C. A.
Coban-Akdemir, Zeynep
Lopez, Keila N.
Hall, Nancy J.
Dickerson, Heather
Nicosia, Annarita
Fernbach, Susan
Boone, Philip M.
Gambin, Tomaz
Karaca, Ender
Gu, Shen
Yuan, Bo
Jhangiani, Shalini N.
Doddapaneni, HarshaVardhan
Hu, Jianhong
Dinh, Huyen
Jayaseelan, Joy
Muzny, Donna
Lalani, Seema
Towbin, Jeffrey
Penny, Daniel
Fraser, Charles
Martin, James
Lupski, James R.
Gibbs, Richard A.
Boerwinkle, Eric
Ware, Stephanie M.
Belmont, John W.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1U54 HD083092, 5RO1 HL090506)
Doris Duke Charitable Foundation (2013096)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG006542)
Article History
Received: 9 March 2018
Revised: 29 October 2018
Accepted: 7 November 2018
First Online: 8 January 2019
Compliance with ethical standards
:
: JRL holds stock ownership in 23andMe, Inc. and Lasergen, Inc., is a paid consultant for Regeneron Pharmaceuticals and is a co-inventor on multiple United States and European patents related to molecular diagnostics. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered in the Baylor Genetics Laboratories. JRL is on the Scientific Advisory Board of Baylor Genetics. JWB is a fulltime employee of Illumina Inc, but all work was performed under the listed affiliation. AHL is a fulltime employee of Regeneron Pharmaceuticals, but all analyses were performed under the listed affiliation.